二十世纪80年代，伴随着中国改革的发展，辉瑞进入到中国市场，从此开始了长期投身于中国医药卫生事业发展的历程。辉瑞在中国的业务包括人用药品、胶囊、以及动物保健三大领域。
In the 1980's, following in tow with the progress of China's
opening and reform, Pfizer entered the China market with a long
term vision for development. Pfizer now has three business segments
in China: pharmaceutical, capsule and animal health products.
|
 |
辉瑞一直致力于推动中国人民健康事业的发展，不断引进、生产和推广创新药品，为提高中国人民的医疗保健水平努力。与众不同的是，辉瑞所有在中国上市的创新药品均与全球同步上市。凭借无与伦比的药品组合，辉瑞在心血管科、内分泌科、呼吸系统和感染性疾病、精神科、关节炎和其它炎症、泌尿科、癌症、眼科疾病和其他许多医学领域均保持领先水平,这也使我们的产品在中国市场的占有率能长期居于所有外资制药企业之首。
Pfizer is committed to the long-term development of China's healthcare
environment and strives to improve Chinese healthcare through continuing
to introduce, manufacture and market many of our leading innovative
medications. We are distinctive in our pursuit to make these available
to Chinese patients at the same time of their introductions globally.
With an unequalled product portfolio, Pfizer China maintains category
leadership in the therapeutic areas of cardiovascular disease, endocrinology,
neuroscience, arthritis and other inflammatory diseases, infectious
disease, urology, ophthalmology and oncology. The depth of our reach
has enabled us to hold the highest percentage of market share of any
foreign pharmaceutical company in China.
辉瑞在各级政府、社会各界的广泛支持下，在中国的制药业务得到迅速发展，各项目累计投资总额超过5亿美元，成为在华投资最大的外资制药企业之一。辉瑞先后在大连、苏州、无锡投资建立了符合国际领先标准的现代化制药生产设施。其中，大连工厂是国内首家获得政府颁发的0001号GMP认证证书的工厂。作为辉瑞全球生产集团的一部分，辉瑞在中国的每个工厂都致力于生产高质量的创新药品，认真遵循“追求品质”这一重要的价值观念，使每一个产品都符合世界先进的药品质量标准。同时，不断改进和创新、努力降低生产成本、创造并保持其在本行业内最优异的环保、健康和安全方面的业绩。
With the support of various levels of the Chinese government and the
public sectors, Pfizer's operations in China have developed rapidly.
With an investment of more than US$500 million, Pfizer is one of the
largest foreign pharmaceutical enterprises in China. Pfizer successfully
established state-of-the-art plants in Dalian, Suzhou and Wuxi. The
Dalian plant was the first in China to receive GMP certification.
As part of a globally integrated Pfizer Global Manufacturing organization,
we are committed to making "Quality" one of our core values
and to producing products that fit our values. Meanwhile, we continue
to pursue innovation, improve product costs, and maintain the industry's
highest environmental, health and safety standards.
辉瑞在中国所取得的成就使辉瑞坚定了在中国长期发展的信心。辉瑞于1997年在北京成立管理中心，并相继在国内各大中城市建立了多个办事机构；2004年，又在上海成立辉瑞投资有限公司暨辉瑞中国地区总部，这体现了中国在辉瑞全球战略中的重要位置。未来五年中，辉瑞计划在中国上市15个创新药品，为过去五年间的三倍，这无疑将更好地服务中国患者，贡献社会。
Pfizer's success in China has solidified our faith in the achievability
of the long-term development of China's healthcare environment.
Pfizer opened many branch offices in most major cities throughout
China. In 1997, Pfizer established its China management center in
Beijing; in 2004, established the Pfizer Investment Co.,Ltd. and
the Pfizer China Regional Headquarters in Shanghai to integrate
and oversee all of Pfizer's China operations. These milestones have
made China a priority in Pfizer's global strategy. In the coming
five years, Pfizer plans to introduce 15 innovative products in
the China market, three times the number of products launched in
the past five years. This will further serve to benefit Chinese
patients and contribute significantly to all of society. |
